MedCity News July 28, 2021
The engineered viruses used to deliver gene therapies can spark complications and they can’t be re-dosed. Ring Therapeutics says viruses that evolved with humans can be better viral vectors and the startup has raised $117 million in new financing to continue its research.
Gene therapy reaches its cellular destination aboard an engineered virus, but the journey is not always problem free. Adeno-associated virus (AAV), the virus that is the backbone of many approved and experimental gene therapies, is foreign to the body and can therefore prompt dangerous immune responses. Even if those complications don’t develop, any antibodies the immune system produces against the viral vector means a patient can’t be given a second dose if needed because the antibodies will...
Today's Sponsors
Today's Sponsor